iCANSleep
A Smartphone App to Treat Insomnia in Cancer Survivors
Do you have difficulty falling or staying asleep? Have you previously been diagnosed with cancer?
If so, we are interested in hearing from you!
About the Study
This study is open to individuals who live in or around St. John’s, NL, who have difficulties with sleep and have at one point been diagnosed with cancer.
iCANSleep is an evidence-based insomnia treatment app that will be tailored to the needs and preferences of cancer survivors. We are currently looking for cancer survivors who have struggled with insomnia to participate in a brief workshop to test the design of iCANSleep and answer questions relating to the
usability, flow, and presentation of the app. The study team is flexible and will work with you and your schedule for booking.
Participation in this study involves:
- One 10-minute questionnaire
- One 30-minute workshop with a Memorial University researcher
- $15 compensation
Are you considering joining the study? Contact us below (or email icansleepapp@gmail.com) for more details!
If you have questions regarding your rights as a research participant, please contact the Health ResearchEthics Authority at (709) 777-6974 or info@hrea.ca
Contact Us
Sleep, Health, & Wellness Lab
Department of Psychology, Memorial University, 232 Elizabeth Avenue, St. John's, Newfoundland
Phone: (403) 505-0419 OR (709) 864-8035 Email: icansleepapp@gmail.com
Study Findings
Click below to find out more about the results of this study:
Published Abstracts
IPOS 2022 - 376 | Qualitative Assessment of Needs and Preferences for a Smartphone App to Treat Insomnia in Cancer Survivors
SLEEP 2023 - 0884 User Needs and Preferences for a Smartphone App to Treat Insomnia in Cancer Survivors
SLEEP 2023 - 0868 Low-Fidelity Usability Testing of a Smartphone App to Treat Insomnia in Cancer Survivors
Our Partners
Project Funding
This research is funded by a Canadian Cancer Society Emerging Scholar Award (Survivorship) (grant #707146) and the Beatrice Hunter Cancer Research Institute, with funds provided by the Canadian Cancer Society’s JD Irving, Limited – Excellence in Cancer Research Fund.
